Conference Coverage

Puzzling, unique ECG from pig-to-human transplanted heart


 

FROM AHA 2022

In the first transplant of a genetically altered pig heart into a human in January, initial unexpected, prolonged ECG readings apparently did not affect the heart’s function, although the organ suddenly began to fail at day 50.

A study of these ECG changes, scheduled for presentation by Calvin Kagan, MD, and colleagues at the American Heart Association scientific sessions, offers insight into this novel operation.

As widely reported, the patient, 57-year-old David Bennett of Maryland, had end-stage heart disease and was a poor candidate for a ventricular assist device and was ineligible for a human heart, when he consented to be the first human to be transplanted with a pig heart that had a number of genes added or subtracted with the goal, in part, to prevent rejection.

The first pig-to-human heart transplant, performed at University of Maryland Medical Center, Baltimore University of Maryland Medical Center

The first pig-to-human heart transplant, performed at University of Maryland Medical Center, Baltimore

The heart initially performed well after it was transplanted in an operation at the University of Maryland School of Medicine (UMSOM) in Baltimore on Jan. 7, but failed in the second month, and Mr. Bennett died on March 9.

The Food and Drug Administration had granted emergency authorization for the surgery through its expanded access (compassionate use) program, coauthor Muhammad Mohiuddin, MD, said in an interview.

“We have learned a lot and hope we can do more,” said Dr. Mohiuddin, scientific and program director of the cardiac xenotransplantation program at UMSOM.

“Suddenly on day 50, the heart started to get thicker and was not relaxing enough,” explained senior author Timm-Michael Dickfeld, MD, PhD, director of electrophysiology research at UMSOM. A biopsy revealed substantial buildup of interstitial fluid that restricted movement. The fluid was replaced by fibrous tissue, leading to irreversible damage.

Persistent, prolonged ECG parameters

In the heart from a genetically modified pig, three genes associated with antibody-mediated rejection and a gene associated with pig heart tissue growth had been inactivated and six human genes associated with immune acceptance had been added. The donor pig was supplied by Revivicor (Blacksburg, Va.).

The patient’s immunosuppressant therapy included an experimental antirejection medication (Kiniksa Pharmaceuticals; Lexington, Mass.).

The patient had daily 12-lead ECGs after the transplant.

In prior research using a pig heart transplanted into a pig body, ECG readings showed a short PR interval (50-120 ms), short QRS duration (70-90 ms) and short QT intervals (260-380 ms).

However, in the transplanted xenograft heart, the initial ECG readings showed a longer PR interval of 190 ms, QRS duration of 138 ms, and QT of 538 ms.

Prolonged intrinsic PR intervals remained stable during the postoperative course (210 ms, range 142-246 ms).

QRS duration also remained prolonged (145 ms, range 116-192 ms), but shortened during the postoperative course (days 21-40 vs. 41-60: 148 ms vs. 132 ms; P < .001).

Increased QT persisted (509 ms, range 384-650 ms) with dynamic fluctuations. The shortest QT duration was observed on day 14 (P < .001).

“In a human heart, when those parameters get longer, this can indicate signs of electrical or myocardial disease,” Dr. Dickfeld explained in a press release from the AHA.

“The QRS duration may prolong when, for example, the muscle and the electrical system itself is diseased, and that is why it takes a long time for electricity to travel from cell to cell and travel from one side of the heart to the other,” he said.

“In the human heart, the QT duration is correlated with an increased risk of abnormal heart rhythms,” he noted. “In our patient, it was concerning that the QT measure was prolonged. While we saw some fluctuations, the QT measure remained prolonged during the whole 61 days.”

Pages

Recommended Reading

PCI fails to beat OMT in ischemic cardiomyopathy: REVIVED-BCIS2
Federal Practitioner
No benefit of routine stress test POST-PCI in high-risk patients
Federal Practitioner
Evolocumab benefits accrue with longer follow-up: FOURIER OLE
Federal Practitioner
Patisiran benefits ATTR amyloidosis with cardiomyopathy: APOLLO-B
Federal Practitioner
Heparin pretreatment may safely open arteries before STEMI cath
Federal Practitioner
TAVR now used in almost 50% of younger severe aortic stenosis patients
Federal Practitioner
Add PCSK9 inhibitor to high-intensity statin at primary PCI, proposes sham-controlled EPIC-STEMI
Federal Practitioner
SMART-CHOICE 3-year results support dropping aspirin after PCI
Federal Practitioner
New deep dive into Paxlovid interactions with CVD meds
Federal Practitioner
Combo thrombolytic approach fails to reduce ICH in stroke
Federal Practitioner